<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838539</url>
  </required_header>
  <id_info>
    <org_study_id>3144A1-2205</org_study_id>
    <secondary_id>B1891016</secondary_id>
    <nct_id>NCT00838539</nct_id>
  </id_info>
  <brief_title>Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1 Study Of Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puma Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puma Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify the maximum tolerated dose(s) of neratinib
      in combination with temsirolimus in subjects with solid tumors. This study will also include
      a preliminary evaluation of efficacy, and assessment of pharmacokinetic (PK) parameters of
      the combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose (MTD) toxicity contour of the combination of neratinib and temsirolimus.</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the recommended phase 2 dose</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess pharmacokinetic parameters of neratinib and temsirolimus in combination</measure>
    <time_frame>Approximately 24 months (post MTD confirmation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gather additional safety and tolerability information to inform the recommended phase 2 dose combinations</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore preliminary evidence of antitumor activity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Neoplasms</condition>
  <condition>Malignant Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neratinib + Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 dose finding study incorporating an Up and Down study design evaluating up to 16 dose combinations of neratinib in combination with temsirolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <description>neratinib 40mg tablets will be taken orally in doses of either 120mg, 160mg, 200mg OR 240mg daily dose, for as long tolerated and the disease under study does not worsen.</description>
    <arm_group_label>Neratinib + Temsirolimus</arm_group_label>
    <other_name>HKI-272</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus will be administered intravenously once a week, at either 15mg, 25mg, 50, or 75mg, for as long as tolerated and the disease under study does not worsen.</description>
    <arm_group_label>Neratinib + Temsirolimus</arm_group_label>
    <other_name>Torisel, temsr, CCI-779</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of advanced or metastatic solid tumor.

          -  Measurable disease per Response Criteria in Solid Tumors (RECIST criteria).

          -  Incurable cancer, with disease progression following at least 1 conventional or
             standard therapy for locally advanced or metastatic disease.

          -  Negative pregnancy test for women of child bearing potential.

        Exclusion Criteria:

          -  Chronic treatment with corticosteroids.

          -  Primary central nervous system (CNS) tumors and active metastases.

          -  Presence of clinically significant or uncontrolled cardiac disease.

          -  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a
             major symptom.

          -  Symptomatic or prior history of non-infectious interstitial pneumonitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Puma</last_name>
    <role>Study Director</role>
    <affiliation>Biotechnology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 22, 2016</lastchanged_date>
  <firstreceived_date>February 5, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neratinib in combination with Temsirolimus</keyword>
  <keyword>solid tumors</keyword>
  <keyword>phase 1</keyword>
  <keyword>dose finding study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
